Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955357 · ClinicalTrials.gov registry record · Phase 4
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
A Phase 4 study of Partial Epilepsies, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 461
- Enrollment target
- 20
- Study locations
NCT00955357 is a Phase 4 study of Partial Epilepsies that has completed, run by UCB Pharma. The registered enrollment target is 461 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT00955357, a Phase 4 study of Partial Epilepsies, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 461 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects who have received treatment with at least 2 AEDs.
Conditions Studied
Interventions
- DRUG Lacosamide
Study Locations (20)
Georgia
- 108 - Atlanta
- 112 - Atlanta
- 124 - Augusta
- 115 - Macon
- 118 - Rome
Florida
- 156 - Clearwater
- 157 - Destin
- 140 - Hollywood
- 161 - Ocala
California
- 103 - Irvine
- 123 - Rancho Mirage
Kentucky
- 102 - Bowling Green
- 117 - Paducah
Louisiana
- 107 - Houma
- 145 - Ruston
Maryland
- 101 - Annapolis
- 162 - Waldorf
Illinois
- 128 - Flossmoor
Iowa
- 130 - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955357
The ClinicalTrials.gov registry entry for NCT00955357 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Partial Epilepsies appearing as the primary indexed condition, and to 1 intervention - of which Lacosamide is the first listed.
NCT00955357 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Georgia, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00955357 about?
NCT00955357 is a clinical study titled "Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures". To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects who have received treatment with at least 2 AEDs.
What is the current status of trial NCT00955357?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 461 participants. The study started on 2009-08. Estimated completion is 2013-08.
What conditions does trial NCT00955357 study?
This clinical trial studies the following conditions: Partial Epilepsies.
What interventions are being tested in trial NCT00955357?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00955357?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00955357 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.